PVI
CRDF icon

Pura Vida Investments’s Cardiff Oncology CRDF Stock Holding History

Pura Vida Investments’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-100,000
Closed -$1.8M – 222
2020
Q4 		$1.8M Buy
+100,000
New +$1.76M 0.07% 148

Other funds holding CRDF

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Pura Vida Investments's CRDF Position: Q1 2021 in Review

Pura Vida Investments sold out of Cardiff Oncology (CRDF) in Q1 2021, closing a stake of 100,000 shares — an estimated $1.8M sold.

Pura Vida Investments first reported a position in CRDF in Q4 2020 and held it in 1 quarter. The position peaked at $1.8M in Q4 2020. 73 funds tracked by Wall St. Rank hold CRDF as of Q1 2021.

  • Pura Vida Investments reported no remaining Cardiff Oncology position as of Q1 2021 after selling out during the quarter.
  • Pura Vida Investments sold 100,000 Cardiff Oncology shares in Q1 2021, an estimated $1.8M.
  • Pura Vida Investments first reported a position in Cardiff Oncology in Q4 2020 and held it in 1 quarter.
  • Pura Vida Investments's Cardiff Oncology position peaked at $1.8M in Q4 2020.
  • 73 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2021.

Based on Pura Vida Investments's 13F filing for Q1 2021, filed 12 May 2021.